Research programme: capsid assembly inhibitors - Arbutus Biopharma

Drug Profile

Research programme: capsid assembly inhibitors - Arbutus Biopharma

Alternative Names: AB-423; Core protein inhibitors - Arbutus

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Baruch S. Blumberg Institute; Drexel University College of Medicine; Enantigen Therapeutics
  • Developer Arbutus Biopharma
  • Class Hepatoprotectants; Small molecules
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 19 Dec 2016 Arbutus Biopharma and Spring Bank Pharmaceuticals enter into a preclinical collaboration for combination of SB 9200 and AB 423 for Hepatitis B
  • 01 Oct 2016 Data from preclinical studies in Hepatitis B presented at the American Association for the Study of Liver Diseases (AASLD-2016)
  • 30 Aug 2016 Arbutus terminates its licence for VLP technology with Kuros
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top